Markus Y Mapara, MD
Hematology
Blood and Marrow Stem Cell Transplantation, Cancer Care, Medical Oncology
Accepting New Patients
Virtual Visits/Telehealth
Overview
Dr. Mapara is Professor of Medicine at Columbia University Medical Center and the Director of the Blood and Marrow Transplantation (BMT)/Cell Therapy Program at New York Presbyterian Hospital/Columbia University Medical Center. Dr. Mapara graduated from the University of Heidelberg Medical School/Germany, and received his post-graduate training in Internal Medicine and Hematology/Oncology at the Universities of Heidelberg and the University Medical Center Charite of the Humboldt University of Berlin in Germany. In addition, he completed a research fellowship at the Transplantation Biology Research Center of the Massachusetts General Hospital at the Harvard Medical School in Boston. As Assistant Professor of Medicine, he headed the Hematologic Intensive Care Unit and served as deputy director of the Stem Cell Transplantation unit at the University Medical Center Charite in Berlin, Germany. Before coming to Columbia, Dr. Mapara was Associate Professor of Medicine (with tenure) at the University of Pittsburgh Cancer Institute and served as the Director of the Adult Hematopoietic Stem Cell Transplantation Program. Dr. Mapara specializes in the care of patients with sickle cell disease and certain blood cancers (Multiple Myeloma, Amyloidosis) undergoing bone marrow transplantation and gene therapy. His research is focused on developing novel approaches to make bone marrow transplantation and cell therapy safer for patients.
Areas of Expertise / Conditions Treated
- Amyloidosis
- Bone Marrow Transplantation
- Gene Therapy
- Leukemia
- Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndrome
- Sickle Cell Anemia
Academic Appointments
- Professor of Medicine at CUMC
Administrative Titles
- Director, Adult Blood and Marrow Transplantation Program, Columbia University Medical Center
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
Languages
- French
- German
Gender
- Male
Schedule an Appointment
Virtual Visits/Telehealth
Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.
Phone Appointments
New and Existing Patients:
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
161 Fort Washington Avenue
New York, NY 10032
Phone:
Fax:
Insurance Accepted
Aetna
- Aetna Signature Administrators
- NYP Employee Plan
- NY Signature
- POS
- Student Health
Affinity Health Plan
- Medicaid Managed Care
AgeWell
- Medicare Managed Care
- Special Needs
Amida Care
- Special Needs
Cigna
- EPO
- Great West (National)
- HMO
- Medicare Managed Care
- POS
- PPO
Emblem/GHI
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross/Blue Shield
- EPO
- PPO
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
Fidelis Care
- Essential Plan
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Leaf (Exchange)
- Medicare Managed Care
Local 1199
- Local 1199
MagnaCare (National)
- MagnaCare
Medicare
- Railroad
- Traditional Medicare
Multiplan
- Multiplan
MVP Health Care
- Child/Family Health Plus
- Essential Plan
- HMO
- Medicaid Managed Care
Quality Health Management
- Quality Health Management
RiverSpring
- Special Needs
TRICARE
- TRICARE
UnitedHealthcare
- Compass (Exchange)
- Empire Plan
- HMO
- Medicaid (Community Plan)
- Oxford Freedom
- Oxford HMO
- Oxford Liberty
- POS
- PPO
VNSNY CHOICE
- Medicare Managed Care
- SelectHealth
WellCare
- Medicare Managed Care
- New Jersey Services (Medicaid Managed Care)
World Trade Center Health Plan
- World Trade Center Health Plan
*Please contact the provider’s office directly to verify that your particular insurance is accepted.
Credentials & Experience
Education & Training
- University of Heidelberg (Germany)
- Internship: University of Heidelberg (Germany)
- Residency: Humboldt University, Faculty of Medicine (Germany)
- Fellowship: Humboldt University, Faculty of Medicine (Germany)
Board Certifications
- Hematology
- Medical Oncology
America's Top Doctor
NY Top Doctor
Research
The research in this laboratory is primarily focused on developing new approaches to improve the outcome of patients with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation.
Selected Publications
- Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. The Lancet Oncology. 2014;15(1):87-95. 4103793
- Stenger EO, Rosborough BR, Mathews LR, Ma H, Mapara MY, Thomson AW, Turnquist HR. IL-12hi rapamycin-conditioned dendritic cells mediate IFN-gamma-dependent apoptosis of alloreactive CD4+ T cells in vitro and reduce lethal graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014;20(2):192-201. 3964782
- Ganjoo KN, de Vos S, Pohlman BL, Flinn IW, Forero-Torres A, Enas NH, Cronier DM, Dang NH, Foon KA, Carpenter SP, Slapak CA, Link BK, Smith MR, Mapara MY, Wooldridge JE. Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcgammaRIIIa Patients with Previously Treated Follicular Lymphoma. Leukemia & lymphoma. 2015;56(1):42-8.
- Mapara MY. Reprogramming donor T cells for adoptive immunotherapy. Immunotherapy. 2013;5(12):1287-9.
- Mapara MY. The quest for the optimal conditioning regimen: some answers, more questions. Biology of blood and marrow transplantation 2013;19(9):1275-6.
- Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(33):4199-206.
- Monaghan SA, Dai L, Mapara MY, Normolle DP, Gollin SM, Lentzsch S. Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide. Leukemia & lymphoma. 2013;54(9):1965-74. 4208434
- Qu Z, Fu J, Ma H, Zhou J, Jin M, Mapara MY, Grusby MJ, Xiao G.2012. PDLIM2 restricts Th1 and Th17 differentiation and prevents autoimmune disease. Cell Biosci. 2(1):23. [Epub ahead of print] PMID: 2273140
- Lentzsch S, O'Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, Burt S, Boyiadzis M, Roodman GD, Mapara MY, Agha M, Waas J, Shuai Y, Normolle D, Zonder JA Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood. 2012. 119(20):4608-13 PMID: 22451423
- Stenger EO, Turnquist HR, Mapara MY, Thomson AW.2012. Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood. 2012. 119:5088-103. PMID: 22403259
- Ma HH, L. C, Ziegler J, Sepulveda A, Liu A, Okada H, Lentzsch S, Mapara MY.2011. Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. J Clin Invest. 121:2554-69
- Ma HH, Ziegler J, Li C, Sepulveda A, Bedeir, A, Grandis J, Lentzsch S, Mapara MY.2011. Sequential Activation of Inflammatory Signaling Pathways During Graft-versus-Host Disease (GVHD): Early Role for STAT1 and STAT3. Cell.Immunol. 268:37-46
- Li S, Pal R, Monaghan SA, Schafer P, Ouyang H, Mapara M, Galson DL, Lentzsch S.2011. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood. 117:5157-65. Epub 2011 Mar 9.
- Randhawa PS, Farasati NA, Huang Y, Mapara MY. 2011. Shapiro R Viral drug sensitivity testing using quantitative PCR: effect of tyrosine kinase inhibitors on polyomavirus BK replication. Am J Clin Pathol.134:916-20.
- Pal R, Janz M, Galson DL, Gries M, Li S, Johrens K, Anagnostopoulos I, Dorken B, Mapara MY, Borghesi L, Kardava L, Roodman GD, Milcarek C, Lentzsch S. 2009. C/EBP{beta} regulates transcription factors critical for proliferation and survival of multiple myeloma cells.Blood. 114:2890-8. PMID: 19717648
- Feng, R, Anderson, G, Xiao, G, Elliott, G, Leoni, L, Mapara, MY, Roodman, GD, and Lentzsch, S. 2007 SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood, 109: 2130-2138. PMID:17095620
- Mapara MY, Leng C, Kim YM, Bronson R, Lokshin A, Luster A, Sykes M. 2006. Expression of Chemokines in GVHD Target Organs Is Influenced by Conditioning and Genetic Factors and Amplified by GVHR. Biol Blood Marrow Transplant. 12:623-634. PMID:16737935
- Leng C, Gries M, Ziegler J, Lokshin A, Mascagni P, Lentzsch S, Mapara MY. 2006. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp Hematol. 34:776-87. PMID: 16728283
- Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY. 2003. Macrophage inflammatory protein-1alpha (MIP-1{alpha}) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood. 101: 3568-3573PMID: 12506012
- Mapara M.Y., Kim,YM, Marx JE, Sykes M 2003. DLI-mediated GVL effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of GVL effects following conversion to full donor chimerism. Transplantation 76:297-305. PMID: 12883182
- Mapara M. Y., Y.-M. Kim, S.P. Wang, R. Bronson, D.H. Sachs and M. Sykes. 2002. Donor lymphocyte infusions (DLI) mediate superior GVL effects in mixed compared to fully allogeneic chimeras: A critical role for host antigen presenting cells. Blood 100: 1903-1909. PMID: 12176915
- Mapara, M.Y., I.J. Körner, M. Hildebrandt, R. Bargou, D. Krahl, P. Reichardt, and B. Dörken. 1997. Monitoring of Tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and RT-PCR. Blood 89:337 - 344.PMID: 8978310
- Wolff, G., I.J. Körner, W. Arnold, A. Schuhmacher, B. Dörken, and M.Y.Mapara. 1998. Purging of Breast Cancer Cells by Short Term Administration of Cytosine Deaminase and 5 Fluorocytosine Prevents Tumor Growth after Transplantation Hum Gene Ther 9:2277-84.PMID: 9794211